In a report released today, Brandon Folkes from Cantor Fitzgerald maintained a Buy rating on Collegium Pharmaceutical (COLL), with a price target of $35. The company’s shares closed yesterday at $17.34.
“We expect upwards earnings revisions to levels not reflected in FactSet consensus to drive COLL shares higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $35 price target. The Disclosure Section may be found on pages 5 – 6.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $35 price target.”
According to TipRanks.com, Folkes is a 1-star analyst with an average return of -1.0% and a 37.8% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and ANI Pharmaceuticals Inc.
Collegium Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $32.67, representing an 88.4% upside. In a report issued on March 4, H.C. Wainwright also maintained a Buy rating on the stock with a $30 price target.
The company has a one-year high of $28.91 and a one-year low of $13.10. Currently, Collegium Pharmaceutical has an average volume of 449K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases.